Go to content

CCRM Nordic thanks Anna Falk as she transitions from CSO to the SAB

Date: 25 September 2026

Place: Gothenburg

CCRM Nordic announces that Anna Falk will transition from her role as CSO to a continued position on the Scientific Advisory Board. Having played an important role in CCRM Nordic’s early development, Anna leaves an important legacy in the organization, and we are very pleased that she will remain closely connected to CCRM Nordic through her continued role on the Scientific Advisory Board (SAB).

Since joining CCRM Nordic, Anna has contributed extensive scientific expertise and experience, helping shape the organization’s scientific priorities and supporting its ambition to accelerate the development and commercialization of advanced therapy medicinal products (ATMPs).

In addition to her role as CSO, Anna has led CCRM Nordic’s Scientific Advisory Board, bringing together leading expertise from academia and industry to provide scientific perspectives and strategic guidance as the organization has continued to grow.

“We are very grateful for Anna’s contributions to CCRM Nordic. Her scientific expertise, commitment and perspective have been highly valuable during an important phase in our development. While we will miss having Anna as part of the operational team, we are very pleased that she will remain closely connected to CCRM Nordic through our Scientific Advisory Board,” says Fredrik Wessberg, CEO of CCRM Nordic.

Going forward, the SAB will be led by Michael Delahaye, Chief Technology Officer at CCRM Nordic. Anna will remain a member of the SAB, enabling CCRM Nordic to continue benefiting from her expertise and experience while bringing the leadership of the SAB closer to the organization’s technical and scientific development.

“Anna has built a strong foundation for the SAB, and I look forward to building on that work together with her and the other members. The SAB will continue to bring important external scientific perspectives to CCRM Nordic as we develop our capabilities and take on new challenges,” says Michael Delahaye, CTO of CCRM Nordic.

“I am proud of what we have built and developed together at CCRM Nordic and grateful to have been part of the organization’s journey. I look forward to staying involved through the SAB and continuing to support CCRM Nordic as it enters its next phase of development,” says Anna Falk.

CCRM Nordic would like to thank Anna for her dedication and contributions as CSO and looks forward to continuing to work with her through the Scientific Advisory Board.

 

Contacts

Fredrik Wessberg, fredrik.wessberg@ccrmnordic.se 

About CCRM Nordic:

CCRM Nordic is a leading organization dedicated to advancing research, development, and commercialization of advanced therapy medicinal products (ATMPs). With a focus on innovation and collaboration, CCRM Nordic strives to accelerate the translation of scientific discoveries into tangible therapies that address unmet medical needs.

About CCRM:

CCRM is a global, public-private partnership headquartered in Canada, established with seed funding provided by the Government of Canada, the Province of Ontario, and leading academic and industry partners. CCRM supports the development of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy. A network of researchers, leading companies, investors and entrepreneurs, CCRM accelerates the translation of scientific discovery into new companies and marketable products for patients, with specialized teams, dedicated funding, and unique infrastructure. In 2022, CCRM established OmniaBio Inc., a pre-clinical to commercial-stage CDMO for manufacturing gene-modified cells and viral vectors for cell and gene therapies. CCRM is hosted by the University of Toronto. Visit at ccrm.ca

How can we assist you?

Talk to us